GPCR Target: Stably human CaSR-expressing HEK-293T
Authors: Moritaka Goto, et al.
Journal: European Journal of Pharmacology, Volume 956, 2023, 175936, ISSN 0014-2999.
Year Published: 2023
Innovation is in Multispan's DNA
Delivering deeper target biology insights, faster identification of higher quality leads, and more physiologically relevant data for clinical translation, powered by unique membrane protein expression approaches and novel assay technologies with 30+ patents.
The Multispan Portfolio
Multispan’s commitment to quality and scientific excellence extends to every product in its portfolio of ready-to-use tools. These products produce data with the consistency, reliability, and physiological relevance required to bring better medicines to the clinic.
Advancing Drug Discovery Through Improved High Throughput Screening
MULTISCREEN™ β-Arrestin Sensor Technology
Multispan recognized the need for improved β-Arrestin screening assays and developed a novel HTS technology, MULTISCREEN™ β-Arrestin Sensor technology, that can assess β-Arrestin signaling of native GPCRs in recombinant or primary cells – a critical aspect for assessing receptor physiology.
Our assay kits, reagents and services based on MULTISCREEN™ β-Arrestin sensor technology enable researchers to examine unmodified GPCRs, including endogenously expressed GPCR targets, which provide more relevant data for improved identification and optimization of qualified drug candidates.
Don’t let GPCR tagging bias your results. Find out how to unbias your GPCR signaling research.
Accelerated Covid Antiviral And Vaccine Development
Control and eradication of SARS-Cov-2 will require advanced antivirals and/or a protective vaccine – development of both of which depends on improved knowledge of the virus pathophysiology, identification and therapeutic exploitation of the vulnerabilities of the virus, and characterization of the components of protective immunity.
Multispan has a proven record of complex cell engineering and assay development. Ensure the advancement of your SARS-CoV-2 drug and vaccine development efforts by harnessing the knowledge and expertise of their scientific teams. Contact Multispan today to discuss the design and implementation of your COVID assay.
Innovative Expression Technology
Multispan developed a proprietary technology to enable expression of GPCR proteins in mammalian cells at over a million molecules per cell surface. High expressing cells (HEx™) can be developed into single cell clones and used as a unique source of high quality GPCR proteins for variety of applications:
- Antibody generation using antigens with natural epitopes at high expression level
- Cell-based or membrane receptor binding assays to achieve high signal-to-noise ratio
- Cell-based functional assays for hard-to-express GPCRs from all 3 structurally distinctive GPCR families
- Structural studies as high-quality source of protein for crystallization
MULTISCREEN™ β-Arrestin Sensor Technology
Multispan recognized the need for improved β-Arrestin screening assays and developed a novel HTS technology, MULTISCREEN™ β-Arrestin Sensor technology, that can assess β-Arrestin signaling of native GPCRs in recombinant or primary cells – a critical aspect for assessing receptor physiology.
Our assay kits, reagents and services based on MULTISCREEN™ β-Arrestin sensor technology enable researchers to examine unmodified GPCRs, including endogenously expressed GPCR targets, which provide more relevant data for improved identification and optimization of qualified drug candidates.
Don’t let GPCR tagging bias your results. Find out how to unbias your GPCR signaling research.
Accelerated Covid Antiviral And Vaccine Development
Control and eradication of SARS-Cov-2 will require advanced antivirals and/or a protective vaccine – development of both of which depends on improved knowledge of the virus pathophysiology, identification and therapeutic exploitation of the vulnerabilities of the virus, and characterization of the components of protective immunity.
Multispan has a proven record of complex cell engineering and assay development. Ensure the advancement of your SARS-CoV-2 drug and vaccine development efforts by harnessing the knowledge and expertise of their scientific teams. Contact Multispan today to discuss the design and implementation of your COVID assay.
Innovative Expression Technology
Multispan developed a proprietary technology to enable expression of GPCR proteins in mammalian cells at over a million molecules per cell surface. High expressing cells (HEx™) can be developed into single cell clones and used as a unique source of high quality GPCR proteins for variety of applications:
- Antibody generation using antigens with natural epitopes at high expression level
- Cell-based or membrane receptor binding assays to achieve high signal-to-noise ratio
- Cell-based functional assays for hard-to-express GPCRs from all 3 structurally distinctive GPCR families
- Structural studies as high-quality source of protein for crystallization
Publications & Patents
GPCR Target: MULTISCREENᵀᴹ TR-FRET cAMP 1.0 No Wash Assay Kit
Authors: Jongmin Yoon, et al.
Journal: Biomedicine & Pharmacotherapy, Volume 177, 2024, 117044, ISSN 0753-3322.
Year Published: 2024
GPCR Target: PTHR1
Authors: Daniel B. Hall, et al.
Journal: JBMR Plus, Volume 8, Issue 6, June 2024, ziae045.
Year Published: 2024